title: In vitro and in vivo angiogenic activity of osteoarthritic and osteoporotic osteoblasts is modulated by VEGF and vitamin D3 treatment.
abstract: Vascular Endothelial Growth Factor (VEGF) is a potent angiogenic factor, which also regulates bone remodeling. Osteoblasts not only respond to VEGF stimulation, but also express and synthesize this factor. The present study was aimed to evaluate in vitro differences in VEGF production and expression of cultured human osteoblastic cells derived from healthy donors and from subjects affected by osteoarthritis and osteoporosis, under basal conditions than after vitamin D3, and to investigate the angiogenic activity of culture media obtained by these cells in chick embryo chorioallantoic membrane (CAM) assay. The results showed that normal and pathological osteoblasts produce and express VEGF and 1,25 dihydroxy-vitamin D3 treatment increases protein and m-RNA VEGF levels. In addition culture media of pathological osteoblasts induce a strong angiogenic response, greater than observed with culture medium of normal cells, suggesting the involvement of osteoblast-derived VEGF in the pathogenesis of bone diseases.
authors.affiliation: Rheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia, Ospedale Col. D'Avanzo, Foggia, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Neve
authors.forename: Francesco Paolo
authors.initials: FP
authors.lastname: Cantatore
authors.forename: Addolorata
authors.initials: A
authors.lastname: Corrado
authors.forename: Annamaria
authors.initials: A
authors.lastname: Gaudio
authors.forename: Simona
authors.initials: S
authors.lastname: Ruggieri
authors.forename: Domenico
authors.initials: D
authors.lastname: Ribatti
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002478:Cells, Cultured; D002642:Chick Embryo; D002762:Cholecalciferol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D049033:Chorioallantoic Membrane / Q000098:blood supply; D003470:Culture Media / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic; D010003:Osteoarthritis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D010006:Osteoblasts / Q000378:metabolism* / Q000473:pathology; D010024:Osteoporosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*; D014815:Vitamins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D003470:Culture Media; D042461:Vascular Endothelial Growth Factor A; D014815:Vitamins; D002762:Cholecalciferol